A federal appeals court has ruled that Cell Therapeutics can pursue a claim for nearly $23 million against a former consultant that advised it to market a drug off-label, adding a whole new wrinkle to whistleblower lawsuits. Report [1]
Links:
[1] http://www.pharmalot.com/2009/11/biotech-can-sue-consultant-over-whistleblower-loss/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Pharmalot+%28Pharmalot%29